6th Annual IPO Report

OnMarket

IPOs returned an average of 15.2% for 2021, outperforming the ASX200 by 2.1%.

OnMarket 2021 IPO Report

OnMarket is pleased to release the 6th Annual IPO Report - detailing 2021 IPO activity and providing insight into the Australian IPO Market for 2022.

For regular readers it won’t surprise you that our message is the same as other years. 2021 IPOs have yet again outperformed the market with an average end of year return of 15.2%, outperforming the ASX 200 by 2.1%. 

2021 was a record year for the number of IPOs on ASX, with a total of 204 IPOs on the ASX raising a combined $13.4b. An increase from $5.6b across 79 listings in 2020.

Throughout the first half of the year, there were 67 new listings. Investors in H1 were rewarded, with H1 IPOs outperforming the ASX 200 by 9.3% come 31 December. In H2, IPO volume surged, with 67% of 2021 IPOs occurring in the second half of the year, raising almost 74% of the total capital raised in 2021. 

To download the 2021 IPO Report, or IPO reports from the last 5 years, please follow the links below.

 

Regards,

The OnMarket Team

 

Discover investment opportunities here.

 

Wholesale Live

Baymatob Pty Ltd

AI platform for $5.7B fetal monitoring market, FDA Breakthrough Designation


Baymatob is a medtech company revolutionising maternal care with Oli™, an AI-driven tool for early detection of pregnancy and labor complications. Backed by Perennial, and Scale Investors, Oli targets the $5.7B fetal monitoring market and has FDA Breakthrough Designation (expedited review) to improve outcomes and reduce costly interventions.

$1.91Price
Up to $12 millionSize of Offer
22 Jul 25Offer Open
05 Aug 25Pay By
CSF Register for early access

Bond Conveyancing P/L

Disrupting a $2.2B fragmented conveyancing market

 

Bond Property Lawyers is a tech-enabled national conveyancing firm rapidly gaining market share. With three major new national corporate partnerships set to increase their referral base by 60x, they’re positioned to scale faster than ever. Their streamlined systems and industry-leading client experience have made them a trusted partner across Australia.

CSF Closed Jul 2025

PhycoLife (Venus Shell Systems P/L)

PhycoLife (Venus Shell Systems P/L) Equity Crowdfunding Offer has successfully closed. PhycoLife's core strength lies in their comprehensive mastery of the entire seaweed value chain. They're not simply product sellers; they are fundamental creators, meticulously managing every stage from proprietary indoor marine cultivation and advanced bio-refining to the formulation of market-leading health products.

Fully Funded

$1.85 million

Raised

790

Investors